BioSpace News Archive

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its TALEN® gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK™ cell engager antibodies at the Society for Immunotherapy of Cancer’s 37th Annual Meeting.

MAIA Biotechnology, Inc. announced that the management team will participate in the ThinkEquity Conference.

Bayer, one of the country’s leading life-sciences companies, announced that William Dodero, its current Vice President and Global Head of Litigation, will become the company’s new U.S. General Counsel and Senior Vice President, as well as a member of the U.S. Country Leadership Team.

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the close of U.S. financial markets.

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from DRAGON, a Phase 1 proof-of-concept study of SRK-181 in patients with advanced solid tumors.

Senseonics Holdings, Inc., a medical technology company focused on the design and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Standard BioTools Inc., driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – announced the launch of the X9™ Real-Time PCR System, an innovative high-capacity genomics instrument offering superior efficiency.

Acer Therapeutics Inc. announced that the University of North Carolina Institute for Trauma Recovery has been awarded a $3 million grant from the Department of Defense to investigate the potential of ACER-801 to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2022 earnings release and conference call.